239 related articles for article (PubMed ID: 33392181)
41. A novel gene signature related to fatty acid metabolism predicts prognosis, immune landscape, and drug sensitivity in early-stage lung squamous cell carcinoma.
Xu J; Yu M; Fan W; Feng J
Transl Cancer Res; 2024 Feb; 13(2):525-541. PubMed ID: 38482436
[TBL] [Abstract][Full Text] [Related]
42. The Prognostic Value of the DNA Repair Gene Signature in Head and Neck Squamous Cell Carcinoma.
Ming R; Wang E; Wei J; Shen J; Zong S; Xiao H
Front Oncol; 2021; 11():710694. PubMed ID: 34395285
[TBL] [Abstract][Full Text] [Related]
43. Risk model based on genes regulating the response of tumor cells to T-cell-mediated killing in esophageal squamous cell carcinoma.
Zhang X; Yu C; Zhou S; Zhang Y; Tian B; Bian Y; Wang W; Lin H; Wang LW
Aging (Albany NY); 2024 Feb; 16(3):2494-2516. PubMed ID: 38305770
[TBL] [Abstract][Full Text] [Related]
44. Development of immune gene pair-based signature predictive of prognosis and immunotherapy in esophageal cancer.
Cao K; Ma T; Ling X; Liu M; Jiang X; Ma K; Zhu J; Ma J
Ann Transl Med; 2021 Oct; 9(20):1591. PubMed ID: 34790797
[TBL] [Abstract][Full Text] [Related]
45. [Establishment and validation of prognostic risk score model for esophageal squamous cell carcinoma based on immune related genes].
Liu HR; Jiang GZ; Xin D; Yang YL; Fan QX; Meng XR; Li SL; Liu Y; Xia J; Wang F
Zhonghua Zhong Liu Za Zhi; 2021 Jun; 43(6):666-673. PubMed ID: 34289558
[No Abstract] [Full Text] [Related]
46. Exploration of a Robust and Prognostic Immune Related Gene Signature for Cervical Squamous Cell Carcinoma.
Zuo Z; Xiong J; Zeng C; Jiang Y; Xiong K; Tao H; Guo Y
Front Mol Biosci; 2021; 8():625470. PubMed ID: 33748188
[No Abstract] [Full Text] [Related]
47. A novel tumor microenvironment-related gene signature with immune features for prognosis of lung squamous cell carcinoma.
Han WJ; He P
J Cancer Res Clin Oncol; 2023 Nov; 149(14):13137-13154. PubMed ID: 37479755
[TBL] [Abstract][Full Text] [Related]
48. Clinical Significance and Immunometabolism Landscapes of a Novel Recurrence-Associated Lipid Metabolism Signature In Early-Stage Lung Adenocarcinoma: A Comprehensive Analysis.
Zhu M; Zeng Q; Fan T; Lei Y; Wang F; Zheng S; Wang X; Zeng H; Tan F; Sun N; Xue Q; He J
Front Immunol; 2022; 13():783495. PubMed ID: 35222371
[TBL] [Abstract][Full Text] [Related]
49. A tumor immune microenvironment-related integrated signature can predict the pathological response and prognosis of esophageal squamous cell carcinoma following neoadjuvant chemoradiotherapy: A multicenter study in China.
Wu P; Zhang Z; Yuan Y; Zhang C; Zhang G; Xue L; Yang H; Wang L; Zheng X; Zhang Y; Yuan Y; Lei R; Yang Z; Zheng B; Xue Q; Sun N; He J
Int J Surg; 2022 Nov; 107():106960. PubMed ID: 36257585
[TBL] [Abstract][Full Text] [Related]
50. Ferroptosis-Related lncRNA Signature Correlates with the Prognosis, Tumor Microenvironment, and Therapeutic Sensitivity of Esophageal Squamous Cell Carcinoma.
Zhu J; Zhao Y; Wu G; Zhang X; Chen Q; Yang B; Guo X; Ji S; Gu K
Oxid Med Cell Longev; 2022; 2022():7465880. PubMed ID: 35903713
[TBL] [Abstract][Full Text] [Related]
51. Prognostic value and immune landscapes of cuproptosis-related lncRNAs in esophageal squamous cell carcinoma.
Zhang X; Feng N; Wu B; Guo Z; Pan T; Tao X; Zheng H; Zhang W
Aging (Albany NY); 2023 Oct; 15(19):10473-10500. PubMed ID: 37812189
[TBL] [Abstract][Full Text] [Related]
52. A Novel Prognostic Signature Based on Metabolism-Related Genes to Predict Survival and Guide Personalized Treatment for Head and Neck Squamous Carcinoma.
Li Y; Weng Y; Pan Y; Huang Z; Chen X; Hong W; Lin T; Wang L; Liu W; Qiu S
Front Oncol; 2021; 11():685026. PubMed ID: 34195087
[TBL] [Abstract][Full Text] [Related]
53. Oxidative stress genes in patients with esophageal squamous cell carcinoma: construction of a novel prognostic signature and characterization of tumor microenvironment infiltration.
Liu W; Yang HS; Zheng SY; Luo HH; Feng YF; Lei YY
BMC Bioinformatics; 2022 Sep; 23(1):406. PubMed ID: 36180848
[TBL] [Abstract][Full Text] [Related]
54. A composite score based on immune-related gene prognostic index and m
Yang Y; Cai Z; Huang K; Li M; Wang X; Lin Y; Chen S; Yang Z; Lin Z
Front Genet; 2023; 14():1061569. PubMed ID: 36845378
[No Abstract] [Full Text] [Related]
55. A three-gene signature from protein-protein interaction network of LOXL2- and actin-related proteins for esophageal squamous cell carcinoma prognosis.
Zhan XH; Jiao JW; Zhang HF; Li CQ; Zhao JM; Liao LD; Wu JY; Wu BL; Wu ZY; Wang SH; Du ZP; Shen JH; Zou HY; Neufeld G; Xu LY; Li EM
Cancer Med; 2017 Jul; 6(7):1707-1719. PubMed ID: 28556501
[TBL] [Abstract][Full Text] [Related]
56. A Novel Prognosis Signature Based on Ferroptosis-Related Gene DNA Methylation Data for Lung Squamous Cell Carcinoma.
Wang X; Meng Y; Liu C; Yang H; Zhou S
J Oncol; 2022; 2022():9103259. PubMed ID: 36131791
[TBL] [Abstract][Full Text] [Related]
57. Construction and validation of a prognostic signature based on seven endoplasmic reticulum stress-related lncRNAs for patients with head and neck squamous cell carcinoma.
Zhou M; Li H; Hu J; Zhou T; Zhou L; Li Y
Sci Rep; 2023 Dec; 13(1):22414. PubMed ID: 38104177
[TBL] [Abstract][Full Text] [Related]
58. Deciphering a cell death-associated signature for predicting prognosis and response to immunotherapy in lung squamous cell carcinoma.
Mao G; Yang D; Liu B; Zhang Y; Ma S; Dai S; Wang G; Tang W; Lu H; Cai S; Zhu J; Yang H
Respir Res; 2023 Jul; 24(1):176. PubMed ID: 37415224
[TBL] [Abstract][Full Text] [Related]
59. Clinical significance and inflammatory landscapes of a novel recurrence-associated immune signature in early-stage lung adenocarcinoma.
Zhang C; Zhang Z; Zhang G; Zhang Z; Luo Y; Wang F; Wang S; Che Y; Zeng Q; Sun N; He J
Cancer Lett; 2020 Jun; 479():31-41. PubMed ID: 32201203
[TBL] [Abstract][Full Text] [Related]
60. Identification of TREM2-positive tumor-associated macrophages in esophageal squamous cell carcinoma: implication for poor prognosis and immunotherapy modulation.
Li H; Miao Y; Zhong L; Feng S; Xu Y; Tang L; Wu C; Zhang X; Gu L; Diao H; Wang H; Wen Z; Yang M
Front Immunol; 2023; 14():1162032. PubMed ID: 37187751
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
